Equities research analysts predict that Nektar Therapeutics (NASDAQ:NKTR) will announce sales of $25.89 million for the current quarter, according to Zacks Investment Research. Six analysts have issued estimates for Nektar Therapeutics’ earnings. The highest sales estimate is $27.40 million and the lowest is $24.50 million. Nektar Therapeutics reported sales of $1.09 billion in the same quarter last year, which indicates a negative year-over-year growth rate of 97.6%. The business is scheduled to issue its next quarterly earnings report on Wednesday, August 14th.
According to Zacks, analysts expect that Nektar Therapeutics will report full-year sales of $107.47 million for the current financial year, with estimates ranging from $104.21 million to $111.92 million. For the next fiscal year, analysts anticipate that the company will post sales of $194.75 million, with estimates ranging from $115.24 million to $310.91 million. Zacks’ sales averages are an average based on a survey of analysts that cover Nektar Therapeutics.
Nektar Therapeutics (NASDAQ:NKTR) last issued its quarterly earnings results on Wednesday, May 8th. The biopharmaceutical company reported ($0.68) EPS for the quarter, topping analysts’ consensus estimates of ($0.71) by $0.03. The company had revenue of $28.22 million for the quarter, compared to analyst estimates of $25.45 million. Nektar Therapeutics had a net margin of 55.65% and a return on equity of 37.63%. During the same quarter in the previous year, the business earned ($0.60) earnings per share.
NKTR has been the topic of a number of recent research reports. Cowen set a $200.00 price target on shares of Lululemon Athletica and gave the stock a “buy” rating in a report on Thursday, June 13th. Mizuho reiterated a “buy” rating and set a $81.00 price target on shares of Nektar Therapeutics in a report on Friday, May 24th. BidaskClub lowered shares of Zebra Technologies from a “buy” rating to a “hold” rating in a report on Tuesday, July 16th. Zacks Investment Research lowered shares of Hess Midstream Partners from a “hold” rating to a “sell” rating in a report on Tuesday, May 14th. Finally, ValuEngine lowered shares of Intersect ENT from a “buy” rating to a “hold” rating in a report on Monday, June 3rd. One investment analyst has rated the stock with a sell rating, three have issued a hold rating and nine have given a buy rating to the company’s stock. The company has an average rating of “Buy” and a consensus price target of $68.50.
In related news, CFO Gil M. Labrucherie sold 3,767 shares of the business’s stock in a transaction on Thursday, May 16th. The shares were sold at an average price of $31.37, for a total value of $118,170.79. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, Director Lutz Lingnau sold 10,000 shares of the business’s stock in a transaction on Monday, July 8th. The shares were sold at an average price of $34.63, for a total transaction of $346,300.00. Following the completion of the transaction, the director now owns 33,200 shares in the company, valued at approximately $1,149,716. The disclosure for this sale can be found here. In the last 90 days, insiders sold 219,949 shares of company stock worth $7,285,900. 4.02% of the stock is owned by company insiders.
A number of hedge funds have recently added to or reduced their stakes in NKTR. Meeder Asset Management Inc. raised its holdings in shares of Nektar Therapeutics by 150.2% during the first quarter. Meeder Asset Management Inc. now owns 798 shares of the biopharmaceutical company’s stock valued at $27,000 after purchasing an additional 479 shares during the period. Quantamental Technologies LLC acquired a new position in shares of Nektar Therapeutics during the first quarter valued at about $27,000. CSat Investment Advisory L.P. raised its holdings in shares of Nektar Therapeutics by 279.2% during the fourth quarter. CSat Investment Advisory L.P. now owns 1,073 shares of the biopharmaceutical company’s stock valued at $35,000 after purchasing an additional 790 shares during the period. Gemmer Asset Management LLC raised its holdings in shares of Nektar Therapeutics by 476.8% during the second quarter. Gemmer Asset Management LLC now owns 1,390 shares of the biopharmaceutical company’s stock valued at $49,000 after purchasing an additional 1,149 shares during the period. Finally, Enterprise Financial Services Corp acquired a new position in shares of Nektar Therapeutics during the first quarter valued at about $67,000. Institutional investors and hedge funds own 92.15% of the company’s stock.
Shares of NASDAQ:NKTR traded down $0.10 during mid-day trading on Friday, reaching $31.97. 1,017,889 shares of the company’s stock were exchanged, compared to its average volume of 1,372,475. The firm has a market cap of $5.57 billion, a price-to-earnings ratio of 8.46 and a beta of 2.74. The firm’s fifty day simple moving average is $33.99. The company has a quick ratio of 14.83, a current ratio of 14.94 and a debt-to-equity ratio of 0.21. Nektar Therapeutics has a twelve month low of $29.22 and a twelve month high of $69.76.
Nektar Therapeutics Company Profile
Nektar Therapeutics, a biopharmaceutical company, develops drug candidates for cancer, auto-immune disease, and chronic pain in the United States. The company develops NKTR-181, an orally-available mu-opioid analgesic molecule, which is in Phase III clinical trial for moderate to severe chronic pain; ONZEALD, a topoisomerase I inhibitor that is in Phase III clinical trial for advanced metastatic breast cancer in patients with brain metastases; and NKTR-214, a CD122-preferential interleukin-2 (IL-2) pathway agonist, which is in Phase I to treat immuno-oncology.
Featured Story: What is net income?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Nektar Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nektar Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.